Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (22750)	6/26/1998 6:33:00 PM
From: Rudy Saucillo	Respond to of 32384

Celeryroot, I don't want to take up too much space on this thread discussing CIST, so I'll be brief and provide relevant links. <<Why don't you define for us what you mean by "extreme value play" ??>> CIST has a book value of ~48 cents/share, trades for 16-18 cents/share, has a proprietary lock on human IL-1b, has an ongoing reagents business and is researching therapeutic uses of IL-1b in cancer, infectious diseases, and wound healing. As the result of a litigation settlement with IMNX, they have cash out the wahzoo. They are actively pursuing partnership and merger/acquisition opportunities. <<as far as, "extraordinary patent position" hmmmm not to many seem to agree since it sells for 19 cents, or could it be that the patent is useless>> Current research has identified very real opportunities for use of IL-1b in immunotherapies for cancer and infectious diseases. This potential is covered by CIST patents/licenses and is not reflected in stock price. Check out messages 1193, 1140, 1144, 1124, 1009 on the CIST thread for a few examples. I'll look for comments on the CIST thread! Rudy